Last reviewed · How we verify
subcutaneous immunotherapy
Subcutaneous immunotherapy involves administering allergens or allergen extracts under the skin to build tolerance and reduce allergic reactions.
Subcutaneous immunotherapy involves administering allergens or allergen extracts under the skin to build tolerance and reduce allergic reactions. Used for Allergic rhinitis, Allergic asthma.
At a glance
| Generic name | subcutaneous immunotherapy |
|---|---|
| Also known as | ALK-depot SQ mites, AVANZ |
| Sponsor | ALK-Abelló A/S |
| Drug class | Immunomodulator |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
This treatment works by gradually exposing the body to small, controlled amounts of the allergen, allowing the immune system to adjust and become less reactive over time. The goal is to desensitize the individual and prevent severe allergic reactions.
Approved indications
- Allergic rhinitis
- Allergic asthma
Common side effects
- Local reactions
- Systemic reactions
- Anaphylaxis
Key clinical trials
- Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer (PHASE1, PHASE2)
- Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma (PHASE1)
- Study of Nogapendekin Alfa Inbakicept and iNKT Cells in Critically Ill Adults With Severe Community-Acquired Pneumonia (PHASE3)
- Personalized Immunotherapy in Adults With Advanced Cancers Immunotherapy in Adults With Advanced Cancers (PHASE1)
- Base Editing for Mutation Repair in Hematopoietic Stem & Progenitor Cells for X-Linked Chronic Granulomatous Disease (PHASE1, PHASE2)
- NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial (PHASE2)
- Evaluation of a Digital Tool to Improve Aeroallergen Immunotherapy Adherence. NavigAITme Project (NA)
- The Efficacy and Safety of Narlumosbart in Combination With Stereotactic Body Radiation Therapy to Improve the Efficacy of First-line Chemotherapy Combined With Immunotherapy in Patients With Bone Metastases From Advanced Non-small Cell Lung Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- subcutaneous immunotherapy CI brief — competitive landscape report
- subcutaneous immunotherapy updates RSS · CI watch RSS
- ALK-Abelló A/S portfolio CI